The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted against the breast cancer prospect.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
FDA delays decision on AstraZeneca breast cancer pill
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
AstraZeneca breast cancer pill faces review delay from regulators
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
Pharmalittle: We're reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in…
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo…
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival…
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with a…
